Study of INCB086550 in Select Solid Tumors

Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Participants with following tumor types : non small cell lung cancer, renal cell carcinoma, urothelial carcinoma, hepatocellular carcinoma and melanoma * Measurable disease per RECIST v1.1. * ECOG performance status of 0 to 1 for all tumor types. Urothelial carcinoma allows ECOG of 0 to 2. * Histologically or cytologically confirmed disease-specific diagnosis as per protocol. * Willingness to avoid pregnancy or fathering children Exclusion Criteria: * Prior receipt of an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or treatment with an immune modulator (eg, CTLA-4, GITR, LAG3, TIM3, OX40, ICOS, IL2, 4-1BB, CAR-T). * Receipt of any anticancer therapy or participation in another interventional clinical study. * Radiotherapy within 14 days of first dose of study treatment. * Concomitant treatment with moderate and potent CYP3A4/CYP3A5 inhibitors or inducers. * Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of anemia not requiring transfusion support and any grade of alopecia). Endocrinopathy, if well-managed, is not exclusionary and should be discussed with the medical monitor. * Participant has not recovered adequately from toxicities and/or complications from surgical intervention before starting study drug. * Participants with laboratory values outside of protocol defined ranges Active malignancy of a type not included in the stud…